Wednesday, July 8, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Patents matching “BIOMARIN TECHNOLOGIES B.V.”

15 pharma patents match "BIOMARIN TECHNOLOGIES B.V." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 15
Index total 30,257
Page 1 / 1

Quick answer

This filtered view shows 15 pharmaceutical patents matching "BIOMARIN TECHNOLOGIES B.V." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

15 results for “BIOMARIN TECHNOLOGIES B.V.” · 30,257 patents in full index Clear search

  1. US 12331293

    Bispecific antisense oligonucleotides for dystrophin exon skipping

    BIOMARIN TECHNOLOGIES B.V. · Granted Jun 17, 2025 · Expires Jun 12, 2045

    granted

  2. US 11427820

    Methods and means for efficient skipping of exon 45 in Duchenne muscular dystrophy pre-mRNA

    BIOMARIN TECHNOLOGIES B.V. · Granted Aug 30, 2022 · Expires Aug 25, 2042

    granted

  3. US 11034956

    Oligonucleotide comprising an inosine for treating DMD

    BIOMARIN TECHNOLOGIES B.V. · Granted Jun 15, 2021 · Expires Jun 10, 2041

    granted

  4. US 10913946

    RNA modulating oligonucleotides with improved characteristics for the treatment of Duchenne and Becker muscular dystrophy

    BIOMARIN TECHNOLOGIES B.V. · Granted Feb 9, 2021 · Expires Feb 4, 2041

    granted

  5. US 10876114

    Methods and means for efficient skipping of at least one of the following exons of the human Duchenne muscular dystrophy gene: 43, 46, 50-53

    BIOMARIN TECHNOLOGIES B.V. · Granted Dec 29, 2020 · Expires Dec 24, 2040

    granted

  6. US 10689646

    Treatment of genetic disorders associated with DNA repeat instability

    BIOMARIN TECHNOLOGIES B.V. · Granted Jun 23, 2020 · Expires Jun 18, 2040

    granted

  7. US 10533171

    Oligonucleotide comprising an inosine for treating DMD

    BIOMARIN TECHNOLOGIES B.V. · Granted Jan 14, 2020 · Expires Jan 9, 2040

    granted

  8. US 10246707

    Method for efficient exon (44) skipping in duchenne muscular dystrophy and associated means

    BIOMARIN TECHNOLOGIES B.V. · Granted Apr 2, 2019 · Expires Mar 28, 2039

    granted

  9. US 10179912

    RNA modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy

    BIOMARIN TECHNOLOGIES B.V. · Granted Jan 15, 2019 · Expires Jan 10, 2039

    granted

  10. US 9926557

    Methods and means for efficient skipping of exon 45 in Duchenne muscular dystrophy pre-mRNA

    BIOMARIN TECHNOLOGIES B.V. · Granted Mar 27, 2018 · Expires Mar 22, 2038

    granted

  11. US 9890379

    Treatment of genetic disorders associated with DNA repeat instability

    BIOMARIN TECHNOLOGIES B.V. · Granted Feb 13, 2018 · Expires Feb 8, 2038

    granted

  12. US 9745576

    RNA modulating oligonucleotides with improved characteristics for the treatment of neuromuscular disorders

    BIOMARIN TECHNOLOGIES B.V. · Granted Aug 29, 2017 · Expires Aug 24, 2037

    granted

  13. US 9528109

    Methods and means for efficient skipping of exon 45 in duchenne muscular dystrophy pre-mRNA

    BIOMARIN TECHNOLOGIES B.V. · Granted Dec 27, 2016 · Expires Dec 22, 2036

    granted

  14. US 9499818

    Methods and means for efficient skipping of at least one of the exons 51-53, 55, 57 and 59 of the human duchenne muscular dystrophy gene

    BIOMARIN TECHNOLOGIES B.V. · Granted Nov 22, 2016 · Expires Nov 17, 2036

    granted

  15. US 9243245

    Means and methods for counteracting muscle disorders

    BIOMARIN TECHNOLOGIES B.V. · Granted Jan 26, 2016 · Expires Jan 21, 2036

    granted

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.